Introduction
The myb oncogene, which is unique in its hematopoietic speci®city of transformation, was ®rst discovered in two independently derived avian retroviruses which cause acute leukemia (for review, see Introna et al., 1994) . Both AMV and the E26 viruses encode vMyb proteins that are truncated versions of the cellular c-Myb protein. In addition, the E26 virus expresses a more complex Gag-Myb-Ets fusion protein. The normal c-myb proto-oncogene is expressed at high levels in immature hematopoietic cells. Its expression decreases as these cells dierentiate. On the other hand the AMV v-myb oncogene blocks dierentiation which results in transformation of macrophage precursors.
The c-Myb protein contains three major domains that are important for its function: an N-terminal DNA binding domain, a centrally located transactivation domain (TA), and a C-terminal negative regulatory domain (NR) (Sakura et al., 1989) . The 48 kD v-Myb protein is a truncated form of the 75 kD c-Myb protein which in addition to the N-and Cterminal deletions contains 11 amino acid substitutions. Both the c-Myb and the v-Myb proteins are localized in the nucleus (Klempnauer et al., 1984; Boyle et al., 1984) , have short half-lives and bind to DNA in a sequence-speci®c fashion (Klempnauer and Sippel, 1987; Biedenkapp et al., 1988) .
The c-Myb protein contains three imperfect repeats (repeat R1, R2 and R3) at its N-terminus which are responsible for its DNA-binding activity. The family of Myb proteins is de®ned by the presence of this Myb domain (repeat), a region of approximately 51 amino acids which can be present in multiple copies within a single protein (Lipsick, 1996) . Based on the amino acid sequence, it was suggested that each of the repeats fold into a HTH (helix ± turn ± helix)-related motif similar to those found in repressor proteins of prokaryotes and in homeodomain proteins of eukaryotes. This prediction was recently con®rmed by NMR analysis of c-Myb R2R3 complexed with DNA (Ogata et al., 1994) . Unlike many other DNA-binding domains, the Myb proteins appear to bind to DNA as a monomer (Garcia et al., 1991) .
The AMV v-Myb recognition sequence (PyAAC(T/ G)G) was discovered by selection of random genomic DNA fragments (Biedenkapp et al., 1988) . This consensus sequence was veri®ed with the identification of the E26-inducible mim-1 gene (Ness et al., 1989) , where three such Myb sites are present in the 5'-noncoding region of this gene.
Based on the presence of the Myb consensus sequences in the 5'-¯anking regions, several other candidate Myb-regulated genes have been proposed, including the c-kit proto-oncogene (Yamamoto et al., 1993) , the human CDC2 gene (Ku et al., 1993) , the human hematopoietic stem cell antigen CD34 (Melotti et al., 1994) , the CD13/APN gene (Shapiro et al., 1995) , the human oxytocin receptor gene , the murine neutrophil elastase gene (Nuchprayoon et al., 1994) , the mouse CD4 promoter (Siu et al., 1992) , the human c-myc gene (Evans et al., 1990) , and the N-ras gene (Thorn et al., 1991) . So far little is known about the functional relevance of the Myb recognition sites within these promoters, and none of these potential Myb-regulated genes have been de®nitively linked to the ability of Myb proteins to transform cells or induce leukemia.
N-ras belongs to a highly conserved superfamily of guanine-nucleotide-binding proteins that is found in all eukaryotic organisms (Barbacid, 1987) . N-ras, Hras, and K-ras are three members of this ras family and encode similar yet non-identical proteins that have been implicated in the normal cellular processes of proliferation (Feramisco et al., 1984; Mulcahy et al., 1985) and dierentiation (Bar-Sagi and Feramisco, 1985; Noda et al., 1985; Guerrero et al., 1986) , as well as the process of transformation (Der et al., 1982; Santos et al., 1982) . These 21 kD proteins (p21), serve as signal transducing molecules by conformationally switching from an inactive state (GDP-bound) to an active state (GTP-bound) upon receiving a signal. However, in spite of accumulating knowledge of the expression and function of the N-ras gene, information about its transcriptional regulation is still limited. Although the most commonly reported tumor-associated lesion of ras is a point mutation which generates an oncogenic (activated) protein (Barbacid, 1987) , ras overexpression has also been implicated in the generation of human tumors (Gerosa et al., 1989) and tumor-derived cell lines (Doniger and DiPaolo, 1988) . This indicates that careful regulation of the N-ras gene may be crucial for prevention of oncogenic transformation. Several potential transcription factor binding sites have been identi®ed within the 5'-¯anking region of the human N-RAS gene: AP1-1, AP-2, Ets, Myc-Max/USF, CREB, and Myb (Thorn et al., 1991) . Although these sites have been shown to be protected in footprinting experiments using HeLa nuclear extracts (Thorn et al., 1991) , additional in vitro binding data was only shown so far for the upstream-speci®c factor (USF) (Thorn et al., 1991) .
Besides several SP1 sites, the murine N-ras promoter also contains a potential USF/c-Myc and three potential Myb binding sites. These three sites with the AAC core are located at position 331, 367, and 407 (Figure 1b) , and are conserved from human, to mouse, and to guinea pig. In this study we focused our attention on investigating the function of these Myb sites in regulating transcription of the murine N-ras gene. We show that the potential Myb sites within the N-ras promoter are functionally relevant and reduce the basal promoter activity by 60%.
Results

Multiple potential Myb recognition sites within the N-ras promoter region
Nucleotide sequence analysis revealed that the N-ras promoter contains three potential Myb recognition sites. To test whether the c-Myb DNA binding domain (c-Myb DBD) can speci®cally bind to these sites, we isolated the 209 bp fragment of the N-ras promoter which contains these sites (from nucleotide 240 to 449, region between black dots in Figure 1b ). First we used DNase I footprinting ( Figure 1a ) to test whether bacterially expressed His3R protein (histidine tagged bacterially expressed c-Myb DBD, see Materials and methods) could bind to all of the three potential Myb binding sites speci®cally. The 209 bp long N-ras promoter region was incubated with His3R protein and subjected to the electromobility shift assay after DNase I treatment. The slowest migrating band (a ladder was obtained which suggested that increasing site occupation takes place, data not shown) which represents a saturated His3R-N-ras promoter complex was isolated and analysed on a sequencing gel. The resulting DNase I cleavage pattern with puri®ed His3R protein shows three well-protected sites for the coding strand (see Figure 1a , lanes 1 and 2). The three protected sites centered over the putative Myb binding sites are between positions 314 and 340 (NrasI site), between positions 357 and 374 (NrasII site), and between positions 381 and 414 (NrasIII site). These footprinting results demonstrate that the His3R protein binds to the three Myb-sites within the N-ras promoter speci®cally. A much clearer protected region was observed for NrasI and NrasII than for NrasIII indicating that the His3R protein has a higher anity for these two sites than for the NrasIII site ( Figure 1a) .
Upon inspection of the protected sequences in greater detail (Figure 1b) , the three Myb recognition sites are found to contain the typical pattern of the Myb consensus sequences with the central core element AAC with a G (NrasI site and NrasII site) or a C (NrasIII) at position 4 (®rst A in AAC core is position 1), and a G (all three Nras sites) at position 5. However, both the upstream and the downstream anking sequences are dierent both from the three Myb-sites in the mim-1 promoter (Ness et al., 1989) and from the earlier published consensus sequence obtained by selection of random genomic DNA fragments (Biedenkapp et al., 1988) . To further investigate binding of both the c-Myb DBD (His3R) and the v-Myb DBD (His2R, histidine tagged bacterially expressed v-Myb DBD, see Materials and methods) to all three sites, we tested these Nras sites in EMSA's (Figure 2a and b). In agreement with the results of DNase I footprinting described above, the His3R protein binds to all three Myb-sites speci®cally, whereas the His2R protein only binds speci®cally NrasII and neither NrasI nor NrasIII. These EMSA's also revealed that the His3R protein has a higher anity for the NrasII site than the His2R protein ( Figure 2b ). We therefore conclude that NrasII is the strongest of the three sites and is likely to exert a dominant eect on the overall promoter activity. To further support these ®ndings, we mutagenized the NrasII site from a functional AAACGG element to a nonfuctional ACCCGG element (Dini and Lipsick, 1993) . The EMSA in Figure 2b shows that the obtained His3R-NrasII complex (lane 8) is abrogated after mixing of the His3R protein with the mutagenized ACCCGG element (lane 14). We conclude that the Nras promoter contains three Myb sites that independently bind the c-Myb DBD (His3R) and that the vMyb DBD (His2R) binds to only one of these sites and with a lower anity than His3R.
Using competition EMSA's with the His3R protein, the three Nras sites were tested in comparison to the mim-1A site. This experiment con®rmed that the NrasII site is the strongest of the three sites (with NrasI being stronger than NrasIII), but it is still not as strong as the mim-1A site (results not shown). The NrasI and the NrasII sites have both the same core sequence of AACGG, and the weakest of the three sites, NrasIII site, diers by the exchange of the G at pos. 4 by a C (AACCG). This is very reminiscent to what has been described for the mim-1C site of the mim-1 promoter (Ness et al., 1989) . The mim-1C site which is the weakest of the three mim-1 sites (Ness et al., 1989 ) also shows a dierence in the core sequence at pos. 4 (the G is exchanged to an A at this position). Because two of the three Nras sites show the same core Myb consensus sequence at the mim-1A site the observed dierences in DNA binding must be attributed to the dierence in anking sequences (Figures 1b and 2a) . The strongest of the three mim-1 sites, the mim-1A site, contains a run of six T's downstream of the Myb recognition site which contributes to increased binding of the Myb proteins to this site (unpublished results). To summar-ize, these competition EMSA experiments support the DNase I footprinting results which show that the NrasII site is the strongest of the three sites, but is weaker than the mim1-A site most probably due to sequences¯anking the Myb consensus binding site. (Moscovici et al., 1982) and therefore oer a good in vivo model for these experiments. Both, in vitro translated v-Myb, and v-Myb from nuclear BM2 extract speci®cally bound to NrasII (Figure 3a) , whereas no binding to NrasI and NrasIII was detectable (results not shown). The results of the EMSA experiments with the NrasII site are shown in Figure 3a and, as a comparison, EMSA's using the mim-1A site are shown in Figure 3b . The electrophoretic mobility shift assays with BM2 extracts and the NrasII probe are shown in lanes 6 ± 8 (Figure 3a) . A slower migrating band from BM2 cells, marked vMyb, runs at the same level as the shifted NrasII probe which resulted from incubation with in vitro translated v-Myb protein (lanes 2 and 3). This slower migrating band disappears after addition of BP7 (lane 4: in vitro translated v-Myb protein; lane 8: v-Myb from nuclear BM2 extract, I=BP7) (Garcia et al., 1991) , a Mybspeci®c antiserum (speci®c for a region within the Myb protein, C-terminal to the Myb DNA binding domain, see Figure 5c : Myb-speci®c antisera map), but not after preincubation with the preimmune serum (P) of BP7 (lane 3: in vitro translated v-Myb protein; lane 7: vMyb from nuclear BM2 extract). This observation suggests that the slower migrating band is the speci®c v-Myb-DNA complex. Further evidence stems from incubation of the in vitro translated protein with a dierent Myb-speci®c antibody, m2.7 (speci®c for a similar region of v-Myb like BP7, see Figure 5c : Myb-speci®c antiserum map), impeding the migration even more (lane 5). Taken together, these results identify the slower migrating band as the speci®c v-Myb-DNA complex. Furthermore these data also argue against a BM2-speci®c cofactor for v-Myb DNA-binding because the in vitro translated protein forms a complex with DNA of similar mobility to that formed by v-Myb from BM2 cell nuclei. The additional background bands observed in electrophoretic mobility Figure 3a (lane 2, 9 and 10). The EMSA experiments summarized in this section clearly show that the entire full length v-Myb protein from nuclear BM2 extracts can speci®cally bind to the NrasII site much the same way as it can bind to the mim-1A site ( Figure 3b , identical experiments as in 3a), albeit with lower anity.
Repression of the N-ras promoter by Myb proteins in transient transfections
Transient transfections of quail QT6 cells provide a convenient system for assaying the ability of both cMyb and v-Myb to regulate various promoters containing Myb recognition sequences because these cells lack both v-Myb and c-Myb. We therefore designed a number of reporter constructs containing dierent fragments of the N-ras promoter DNA cloned immediately upstream of the luciferase reporter gene (de Wet et al., 1987; Nordeen, 1988 ) (see Figure 4a ). The dierent reporter constructs contain dierent fragments of the N-ras promoter cloned into pGL2 basic vector (see Materials and methods) which contains a minimal TATA-box upstream of the luciferase gene. pGLNras contains the entire region of the N-ras promoter (between nucleotides 184 to 626, region between black bars in Figure 1b) , pGLNrasDU contains the region downstream of the N-ras promoter which includes the potential Myb binding sites (between nucleotides 296 to 626, see Figure 1b ), whereas pGLNrasDUM only contains the downstream region of the N-ras promoter without any of the potential Myb binding sites (between nucleotides 425 to 626, region between black bars in Figure 1b ). As shown in Figure 4b , we observed that after transient transfection of the dierent reporter constructs into QT6 cells, the N-ras promoter itself has a high basal activity, most probably due to the presence of the GC-rich region which is located downstream of the Myb recognition sites. This region harbors several SP1 sites as well as a USF/c-Myc site (see Figures 1b  and 4a) , and is present in all three constructs. This high basal activity is in comparison to our results with the EW5(7) reporter construct (Dini and Lipsick, 1993) which was included in these sets of trans-activation experiments as an internal control and which did not have any basal activity (results not shown). When expressing several dierent Myb derivatives (c-Myb, vMyb, a c-Myb/VP16 fusion and a v-Myb/VP16 fusion) a repression of the basal activity by an averge of 60% was observed even for those Myb proteins fused to a strong VP16 activation domain. This observed repression appears to require DNA binding by the dierent Myb proteins which were co-expressed in these transfection experiments, because no repression was observed after coexpression of a v-Myb protein which is de®cient in its DNA binding activity (v-Myb364, contains a linker insertion mutation within the DNA binding domain which abolishes DNA binding) (Lane et al., 1990) . Trans-activation studies with the pGLNrasDUM reporter construct further supported that the observed repression with the pGLNras and pGLNrasDU constructs is mostly due to binding of the Myb proteins to the Myb sites, since deletion of all of the three sites resulted in derepression of the N-ras promoter. This derepression seems only partial and not to be as complete as initially expected, but clearly occurs through the Myb sites. In addition, these transient transfection experiments with the full length N-ras promoter revealed that the Myb proteins can ) bind to their target sites and repress transcription rather than activate transcription as initially expected. We have characterized the levels of expression of individual Myb proteins by Western and found them to be similar for each protein (data not shown).
In conclusion these transient transfection experiments are generally in good agreement with the in vitro and in vivo DNA binding data described above: both cMyb and the v-Myb proteins bind to Nras sites within the N-ras promoter in vitro and repress transcription through the Nras sites in vivo.
Dierent conformation of the v-Myb protein upon binding to dierent target sites
Our unexpected result regarding the repression rather than activation of the N-ras promoter by v-Myb led us to investigate whether dierent conformations of vMyb (active or inactive form) could be the basis for the dierent behavior on NrasII or mim-1A. Such a conformational change upon binding to DNA has been proposed for other DNA binding proteins. Examples are the yeast transcriptional activator Mcm1 (Tan and Richmond, 1990 ) and the oncoprotein Ets-1 (Jonsen et al., 1996) . To test the conformational change hypothesis we used electrophoretic mobility shift assays in combination with dierent Myb-speci®c antisera which could result in a supershift or the disappearance of the slower migrating Myb-DNA complex (Figure 5a and b) . Again the speci®c v-Myb-DNA complex was studied with two dierent probes, the NrasII probe (Figure 5a ) and the mim-1A probe (Figure 5b) . The v-Myb-speci®c antisera BP2 and BP5 recognize the N-terminal region of the Myb proteins (Garcia et al., 1991) and are found to interfere with binding of v-Myb to the mim-1A probe (Figure 5b , lane 3 and 5). In addition to the disappearance of the speci®c v-Myb-DNA complex, a supershifted complex was observed after incubation with these antisera (Figure 5b , lane 3 and 5), in much the same way as seen with the Myb-speci®c monoclonal antibody m2.7 (which recognizes the C-terminal part of the Myb protein) (Figure 5b , lane 9). Interestingly a dierent result was obtained for the NrasII probe (Figure 5a ). Again the speci®c vMyb-DNA complex disappears after addition of BP2 (Figure 5a , lane 3 and 5), but with these antisera no supershifts could be detected (compare to m2.7 supershift of the v-Myb-NrasII complex in lane 8). A map of the dierent Myb-speci®c antisera used in these EMSA's is shown in Figure 5c To summarize, we suggest that the v-Myb protein can exist in two dierent conformations, when bound to these two dierent sites. This could explain why the Myb proteins repress transcription by 60% when bound to the N-ras promoter, and at the same time can function as transcriptional activators when bound to the mim-1 promoter (Ness et al., 1989) .
Discussion
The functional analysis of the 5'-region of the murine N-ras gene carried out in this study has yielded information about individual Myb recognition sites and their function in controlling the expression of this gene. Structurally, this TATA-less (Paciucci and Pellicer, 1991) N-ras promoter contains three Myb recognition sequences which are conserved among human, mouse, and guinea pig. Downstream of the proposed Myb sites several Sp1-binding sites are found (Paciucci and Pellicer, 1991) which are characteristic of growth control genes. In addition, the 5'-region of the N-ras gene contains sequences which show homology to the USF/c-Myc consensus binding sites and which may be bound by these transcription factors and therefore may also contribute to the regulation of this gene.
To analyse the biological relevance of these Myb sites we used both in vitro (EMSA and footprint) and in vivo (EMSA with nuclear extracts and transient transfection) methods. Footprinting of the 209 bp region of the murine N-ras promoter with puri®ed His3R protein (c-Myb DBD) revealed that the potential Myb sites within the N-ras promoter can speci®cally be bound by this protein. The His3R protein shows the highest anity for the NrasI and NrasII sites, and a somewhat lower anity for the third site, NrasIII. Analogous experiments with the vMyb DBD (His2R) revealed that the His2R protein binds to NrasII with lower anity than His3R, but does not bind to NrasI and NrasIII. This is consistent with the observation that the His2R shows weaker binding to the mim-1A site than the His3R protein (Dini and Lipsick, 1993) . Such a dierence in DNA binding between these two proteins has also been observed when performing random site selection experiments: the His3R protein was found to bind to a bigger pool of oligonucleotides than the His2R protein (unpublished results). Furthermore, in vivo binding studies with the v-Myb protein from nuclear BM2 extracts showed that the full length v-Myb protein can only bind speci®cally to NrasII and not (Boyle et al., 1986; Evan et al., 1984; Garcia et al., 1991) . ( NrasI or NrasIII. These in vitro and in vivo EMSA experiments combined with the results obtained from the competition experiment (results not shown) strongly suggest that the site NrasII is the strongest and the most functionally relevant of the three sites. When using the entire N-ras promoter as a reporter in transient transfection experiments we observed a high level of activity even before addition of exogenous v-Myb or c-Myb. This trans-activation was repressed by 60% when dierent Myb proteins were coexpressed, including fusions with the strong VP16 activation domain. However, co-expression of the vMyb mutant NdGE364 (contains a linker-insertion mutation in repeat R2 within the Myb-DNA binding domain) which has been shown neither to bind to DNA nor to trans-activate (Lane et al., 1990; Chen and Lipsick, 1993) , did not repress the high basal transactivation of the N-ras promoter. In addition, no such repression was observed with the reporter construct pGLNrasDUM which lacks all of the Myb sites. Therefore, repression appears to require speci®c DNA-binding by the Myb proteins to their target sites within the N-ras promoter. A Myb-induced repression has been described before for the c-erb-2 promoter (Mizuguchi et al., 1995) , but in this case repression partly involves competition between Myb and TFIID since the Myb-binding sites overlap the TATA-box. The murine N-ras promoter is dierent from this example since it does not contain a TATAbox, and therefore binding of the general transcription factor TFIID has not been shown. The transient transfection results together with the EMSA's suggest that both the v-Myb and the c-Myb proteins are capable of binding speci®cally to the Myb-sites within the N-ras promoter in vitro as well as in vivo.
Since Myb is considered to function as a transcriptional activator as has been shown for the mim-1 promoter (Ness et al., 1989) , but can also function as a repressor protein as shown in this study, the question arose if this repression could be attributed to a dierence in protein conformation. The antibody supershift assays together with conventional EMSA's which were done in the last part of this study clearly identi®ed such a dierence in conformation of the vMyb protein when bound to the mim-1A site versus the NrasII site. This ®nding is of particular interest since it suggests that binding of the oncoprotein v-Myb can result in two dierent protein-DNA complex conformations, implying that v-Myb can function as a repressor or activator depending on the promoter to which it binds. Such a conformational change upon binding to DNA has been shown for other DNA binding proteins such as the yeast transcriptional activator Mcm1 (Tan and Richmond, 1990 ) and the c-Ets protein (Petersen et al., 1995; Jonsen et al., 1996) . The idea that the c-Myb protein undergoes a conformational change upon binding to DNA has been proposed before (Dubendor et al., 1992) and has been supported by the recent ®nding that the negative regulatory domain at the c-Myb C-terminus might actually compete for binding of a cellular cofactor to the N-terminus (Dash et al., 1996) . However, the negative regulatory domain at the C-terminus of the cMyb protein is not present in the v-Myb protein. The underlying conformational change that takes place within the v-Myb protein upon binding to these two dierent target sites must therefore be dierent from the conformational change mechanism proposed for the c-Myb protein which requires its C-terminus.
As mentioned above the actual Myb recognition sites of the N-ras promoter are only conserved in the core region AAC G / C G of the Myb element and not in thē anking sequences. All of the experiments done in this study include as a control the mim-1A element. The downstream¯anking sequence of the mim-1A site contains a stretch of 6 T's which is not present in any of the Nras sites. Such a stretch of T's could have a dramatic eect on the conformation of the DNA by inducing a bend immediately downstream of it which in turn might alter the conformation of the bound protein-DNA complex. In related studies, we have investigated the structure of the mim-1A sequence in greater detail and found that the downstream T stretch of the mim-1A sequence increases the anity of the v-Myb protein to this site (unpublished results). How this T stretch actually contributes to the tertiary structure of the vMyb-DNA complex is unclear, but major dierences in DNA structure between the mim-1A-protein and the NrasII-protein complex could profoundly contribute to the dierences observed in this study.
In summary, the c-Myb protein binds speci®cally to the three Myb sites within the N-ras promoter, while vMyb speci®cally binds only to NrasII. Binding of either c-Myb or v-Myb results in an overall repression of the basal activity of the N-ras promoter by 60%. This repression required a functional Myb DNA-binding domain and could not be overcome by fusion to the potent VP16 activation domain. The fact that the vMyb protein appears to adapt two dierent conformations upon binding to two dierent target sites is an interesting and novel observation. This might constitute a major regulatory mechanism by which the vMyb protein modulates the expression of dierent target genes.
Materials and methods
Plasmid construction and oligonucleotides
DNA restriction and modifying enzymes were purchased from New England Biolabs (Beverly, MA). Oligonucleotides were made on an Applied Biosystems (Foster City, CA) model 380B synthesizer. Recombinant DNA manipulations were carried out by using standard techniques (Sambrook et al., 1989) .
Construction of the T7 expression plasmids for the Myb DNA-binding domain (DBD) proteins as well as the full length v-Myb protein (pMT7-His3R, pMT7-His2R and pMT7-dGE) have been described elsewhere (Dini and Lipsick, 1993) . The dierent activator constructs used for the transient transfection assays have been described elsewhere: N-Cla, NEO-CCC (c-Myb) , N-dGE (v-Myb) , , and (Dini and Lipsick, 1993; Lane et al., 1990) .
Reporter constructs for animal cells were constructed by subcloning PCR fragments of dierent length of the N-ras promoter into NheI and HindIII digested pGL2-Basic Vector (Promega) upstream of the TATA-box. The reporter construct pGLNras was obtained by subcloning the 442 bp region between nucleotide 184 and 626 (region between black bars, Figure 1b ) by using primers that encompass this region (PCRP-NRAS#1 : 5'-ACTTGCTAGCACGGGAACGGATT GGC-3', upstream primer with internal NheI site), PCRPNR Figure 1b) by PCR using primers PCRP-NRAS#9 (5'-TCAGCTAGCGGGTTCTCGGGGA GGGG-3', upstream primer with internal NheI site) and PCRP-NRAS#2 (5'-CCATGAAGCTTCCCGCCAGGG-3', downstream primer with internal HindIII site). pGLNras DUM was obtained by subcloning the 201 bp region between nucleotide 425 and 626 (region between black bars, Figure  1b) by PCR using primers PCRP-NRAS#10 (5'-GGCGCT AGCATGGAAGCGAATAAAG-3', upstream primer with internal NheI site) and PCRP-NRAS#2 (5'-CCATGAAGCTT CCCGCCAGGG-3', downstream primer with internal HindIII site). All clones constructed were veri®ed by the dideoxy sequencing method (Sanger et al., 1977) . The double stranded DNA probes used for the EMSA's in Figures 2b, 3 , and 5 are summarized in Figure 2a . The probes were 3' end-labeled by end-®lling with [a-32 P]dATP and Klenow enzyme (New England Biolabs). Unincorporated nucleotides were separated from labeled DNA by gel ®ltration through Sephadex G-25.
Expression and puri®cation of bacterially expressed proteins
Expression of the c-Myb and the v-Myb DNA-binding domain repeats (His3R and His2R) from the pMT7 plasmid derivatives (see Material and methods, plasmid constructions) were performed by using the T7 overexpression system (Studier et al., 1990) . The constructs were transformed into BL21 (DE3) together with plasmid pLysS to reduce background activity of the T7 polymerase. The cells were grown in M9 ZB medium with ampicillin (100 mg/ml) and chloramphenicol (30 mg/ml) at 378C. The cells were induced at OD 600 =0.8 by addition of IPTG to a concentration of 0.4 mM. After 8 ± 12 h incubation, the cells were centrifuged (6000 g, 7 min, 228C) and the pellets were resuspended in buer A (20 mM Tris-Cl, pH 7.5/ 200 mM NaCl/1 mM EDTA) and stored at 7808C. Lysis of the cells was achieved by the freeze/thaw method and sonication on ice. The lysate was centrifuged (9000 g, 50 min, 48C) and the supernatant was applied to a heparin Sepharose column (Pharmacia) and eluted with a linear NaCl gradient from 200 mM to 1000 mM in buer A. The fractions that contained the protein (4830 mM NaCl), were pooled and the buer was changed to buer B (50 mM NaH 2 PO 4 , pH 8.0/200 mM NaCl) by dialysis.
Electrophoretic mobility shift assay (EMSA)
The methods used are essentially as described elsewhere for other DNA binding proteins (Treisman, 1986; Bohrmann et al., 1987) and include separating free DNA from proteincomplexed DNA on electrophoretic mobility shift gels. Binding reactions were carried out in a ®nal volume of 10 ml containing 20 mM Tris-Cl (pH 7.5), 3 mM MgCl 2 , 50 mM NaCl, 15% (v/v) glycerol, and 50 ng/ml of three unspeci®c DNA's (poly(dI-dC), calf thymus, salmon sperm DNA), end-labeled DNA fragment and protein sample. The binding mixture was incubated for 10 min on ice before 7 ml was loaded on to a 0.5 cm slot of a 16 cm, 6% polyacrylamide gel (29 : 1 acrylamide : bisacrylamide) in 0.256TBE buer pre-run for at least 2 h at 10 V/cm. No tracking dyes were added to the sample. Electrophoresis was performed at 10 V/ cm for 1 h and 45 min. The gel was transferred to 3 MM ®lter paper, dried and autoradiographed.
DNase I protection assay
The methods used are essentially as described by Treisman (1986) and include separating free DNA from proteincomplexed DNA with an EMSA. A plasmid containing the promoter region of the murine N-ras gene was digested to completion with Eco0109I and BsmI and the resulting puri®ed 209 bp restriction fragment was selectively 3' end-labeled at the BsmI site (to label the coding strand) by end-®lling with [a- 32 P]dTTP and Klenow enzyme (Feinberg and Vogelstein, 1983) . Binding reactions were carried out in a 20 ml ®nal volume containing 20 mM sodium cacodylate (pH 8.0), 5.3 mM MgCl 2 , 50 mM NaCl, 5% glycerol, end-labeled DNA fragment and protein sample. The binding mixture was incubated for 10 min at 48C before the sample was treated with DNaseI. 1 ml of 100 mM CaCl 2 and 1 ml (10 72 ± 10 74 Kunitz units/ ml) DNaseI were added to the binding mixture, and the reaction was incubated for 90 s at 48C. The reaction was stopped by addition of 1 ml of 0.5 M EDTA and loaded onto a 5% polyacrylamide gel (40 : 1 acrylamide : bisacrylamide) in 45 mM Tris, 45 mM boric acid, and 1.25 mM EDTA. For all assays, the complexed DNA was separated from free DNA on an electrophoretic mobility shift gel. The wet gel wrapped in Saranwrap was autoradiographed for 1 ± 3 h to locate the DNA fragments. The DNA bands were excised from the gel, eluted, and puri®ed from the polyacrylamide matrix (Treisman, 1985) . The samples were then fractionated on denaturing 6 or 8% polyacrylamide gels. Autoradiography was carried out at 7708C using intensifying screens (Ausubel et al., 1987) .
Cell culture, transient DNA transfections, and b-galactosidase and luciferase assays
The AMV-transformed chicken myeloblast cell line (BM2) was maintained at 378C in a humidi®ed atmosphere containing 10% CO 2 . These cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 5% heat-inactivated chicken serum, 5% fetal calf serum, glucose (4.5 g/liter), 16nonessential amino acids, 2 mM Lglutamine, 1 mM sodium pyruvate, streptomycin (100 mg/ ml) and penicillin (100 U/ml).
The methods used to prepare nuclear cell extracts of BM2 cells are essentially as described by Andrews and Faller (1991) . Non-adherent BM2 cells were grown to 1 ± 2610 6 cells/ml, pelleted, and resuspended in 1.5 ml of ice cold PBS (phosphate-buered saline). After transferring the cell suspension to a microfuge tube, the cells were pelleted for 10 s, and resuspended in 400 ml of cold buer A (10 mM HEPES-KOH, pH 7.9 at 48C/1.5 mM MgCl 2 /10 mM KCl/ 0.5 mM DTT/0.2 mM PMSF). A 10 min incubation on ice was given to allow the cells to swell. The cells were vortexed for 10 s and then centrifuged for 10 s after which the supernatant fraction was discarded. The pellet was resuspended in 100 ml of cold buer C (20 mM HEPES-KOH, pH 7.9 at 48C/25% glycerol/1.5 mM MgCl 2 /420 mM NaCl/ 0.5 mM DTT/0.2 mM PMSF) and incubated on ice for 20 min for high salt extraction. Cellular debris was removed by centrifugation for 5 min at 48C and the supernatant which contains v-Myb protein was used directly for EMSA's.
Quail QT6 ®broblasts were grown in Dulbecco's modi®ed essential Eagle's medium (DMEM) supplemented with 5% fetal calf serum, glucose (4.5 g/liter), 16 nonessential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, streptomycin (100 mg/ml), and penicillin (100 U/ml) in a humidi®ed 10% CO 2 -90% air incubator at 378C.
Transient transfections into QT6 quail ®broblasts were performed by a modi®ed calcium phosphate precipitation method (Chen and Okayama, 1987; Ibanez and Lipsick, 1990) . myb-expressing activator plasmids (3 mg), luciferase reporter plasmid (1 mg), carrier tRNA (5.5 mg) and 0.5 mg of internal control plasmid expressing b-galactosidase from the cytomegalovirus promoter (CMV-b-gal) were co-transfected into approximately 10 6 QT6 cells per 10 cm-diameter plate. The cells from each transfection plate were scraped in phosphate-buered saline. Half of these cells were used for luciferase assay (Ausubel et al., 1987; de Wet et al., 1987) and b-galactosidase assay (Sambrook et al., 1989) , the other half was solubilized by boiling for 3 min in sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) loading dyes and subjected to immunoblotting to demonstrate expression of Myb proteins in transfected cells.
